Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal
Source: SeekingAlpha
2026-04-15 00:26:02 ET
Spyre Therapeutics ( SYRE ) has announced the pricing of an upsized public offering of 6.5M shares of common stock at $62.00 per share, to raise about $403.0 million in gross proceeds from this offering, before costs like underwriting discounts. ...
Read the full article on Seeking Alpha
For further details see:
Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal
Spyre Therapeutics Inc.
NASDAQ: SYRE
SYRE Trading
8.99% G/L:
$78.69 Last:
447,563 Volume:
$73.57 Open:
SYRE Latest News
SYRE Stock Data
$2,603,991,883
65,619,664
1.61%
44
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
